<p>Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies</p>

Abstract

Background: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance. Methods: VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in-vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRC-PNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol 940. Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method. Results: The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4±2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7±8.13 nm and −33.5±1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops. Conclusion: In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections.

A novel and water-soluble material for coronavirus inactivation from oseltamivir in the cavity of methyl and sulfated-β-cyclodextrins through inclusion complexation

“…Based on the pattern of the ICs, amorphous materials lose their crystallinity when they undergo complexation, indicating that the OTV has been encapsulated in the cavity of the CDs [44] , [45] . This revealed the OTV molecule is completely amorphized after stable hydrophobic interactions with both the CDs [46] , [47] .…”

Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole‒clove oil transferosomal nanoparticles

“…Finally, a dried extract was obtained by the addition of a small quantity of methanol. It was diluted and measured at an absorbance of 261 nm (El-Emam et al, 2020 ). The following formula was used to calculate the EE%: where Ctotal = theoretical concentration and Cfree = drug concentration in the supernatant fluid.…”

Antifungal Drugs TDM: Trends and Update

“…26 Alternative administration routes, such as inhalation for VRZ, 27,28 ITZ, 29 and 5FC, 30 have given encouraging results. Eye drops, 31 intrastromal injections, 32–34 and ocular inserts 35 have also been shown to yield satisfactory outcomes for fungal keratitis. New innovative galenic formulations, such as oral formulations of AmB for systemic use (iCo-019, encochleated AmB) 36,37 and liposomal VRZ, 38 are being studied and their impact on TDM must be evaluated.…”